mRNA Cancer Vaccine Shows 90% Success Rate in Phase 3 Trials

A revolutionary mRNA cancer vaccine jointly developed by Moderna and Merck has shown a 90% success rate in preventing cancer recurrence during Phase 3 clinical trials involving 12,000 patients across 200 hospitals worldwide.

How It Works

The vaccine, designated mRNA-4157, works by training the immune system to recognize and attack specific mutations in cancer cells. Each vaccine is personalized to the individual patient's tumor, making it a truly bespoke treatment.

Timeline

The companies plan to file for FDA approval by the end of 2026, with potential availability in early 2027. The initial approval would cover melanoma, with expansions to lung and colorectal cancer expected within a year.